Bristol-Myers Squibb (BMS) inked a multi-year strategic agreement with ConcertAI, which focuses on oncology-specific Real-World Data (RWD) and advanced AI for Real-World Evidence (RWE) generation. BMS plans to use Concerto’s Real-World Data and AI platform eurekaHealth to speed up the process through novel health economic outcomes and clinical development synthetic control arm studies.